Evidence map›Paper›PMID 37202657›Full record

ReviewPharmacological reports : PR2023

Molecular mechanism of ferulic acid and its derivatives in tumor progression.

Xingxun Bao, Wei Li, Ruixue Jia, Dandan Meng, Hairong Zhang, Lei Xia

Open access · hybridAbstract readReview
In one paragraph

Review in Pharmacological reports : PR, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
8.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 54 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Ferulic andRSC advances · 2026
    Article
  8. Enhanced cytotoxic activity ofNanoscale advances · 2026
    Article
  9. Article
  10. Review
  11. Ferulic acid: a liver protector.Frontiers in pharmacology · 2026
    Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. The Role of Ferulic Acid in Selected Malignant Neoplasms.Molecules (Basel, Switzerland) · 2025
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Xingxun Bao *School of Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, 250355, People's Republic of China.
Wei Li *Department of Obstetrics and Gynecology, Linyi Third People's Hospital, Linyi, People's Republic of China.
Ruixue JiaSchool of Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, 250355, People's Republic of China.
Dandan MengSchool of Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, 250355, People's Republic of China.
Hairong ZhangDepartment of Obstetrics and Gynecology, Shandong Provincial Third Hospital, Jinan, 250031, People's Republic of China. sdzhhr7211@163.com.
Lei XiaDepartment of Pathology, Shandong University of Traditional Chinese Medicine, Jinan, 250355, People's Republic of China. pathology001@sina.com.ORCID http://orcid.org/0000-0002-8073-6450
Shandong University of Traditional Chinese Medicine · CNLinyi People's Hospital · CNShandong Provincial Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer is a significant disease that poses a major threat to human health. The main therapeutic methods for cancer include traditional surgery, radiotherapy, chemotherapy, and new therapeutic methods such as targeted therapy and immunotherapy, which have been developed rapidly in recent years. Recently, the tumor antitumor effects of the active ingredients of natural plants have attracted extensive attention. Ferulic acid (FA), (3-methoxy-4-hydroxyl cinnamic), with the molecular formula is C

Indexed as

Lung NeoplasmsPhosphatidylinositol 3-KinasesApoptosisCell Line, TumorCell ProliferationCoumaric AcidsHumansProto-Oncogene Proteins c-aktCoumaric Acidsferulic acidPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktDerivativeFerulic acidMechanism of actionNanoliposomeTumor

Identifiers

PMID37202657
PMCPMC10374777
OpenAlexW4377094416

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.